Open AccessREDUCING POST OPERATIVE NAUSEA AND VOMITING (PONV) IN NEUROSURGICAL PROCEDURES: OUR TERTIARY CARE EXPERIENCE
Author(s) -
Abdul Wahid Khan,
AUTHOR_ID,
Azhar Khan,
Anzeen Nazir Kanth,
Suhail Masood Khan,
Anwar Owais,
AUTHOR_ID,
AUTHOR_ID,
AUTHOR_ID,
AUTHOR_ID
Publication year - 2022
Publication title -
international journal of advanced research
Language(s) - English
Resource type - Journals
ISSN - 2320-5407
DOI - 10.21474/ijar01/14104
Subject(s) - palonosetron , nausea , medicine , vomiting , anesthesia , postoperative nausea and vomiting , retching , dose , saline , surgery , antiemetic
Aim:Patients undergoing elective neurosurgical procedures were observed to determine the therapeutic efficacy of two different dosages of palonosetron. Materials and Methods:Patients undergoing elective neurosurgical procedures were randomly allocated to one of three groups: control (n = 30), 0.05 mg palonosetron (n = 30), or 0.075 mg palonosetron (n = 30). At the start of the dura mater closure, the medicines were administered intravenously. Anesthesia was maintained with 1 MAC sevoflurane in a 50/50 combination of air and oxygen. The patients were observed for 72 hours after extubation for postoperative nausea and vomiting. Results:The 0.075 mg palonosetron group had considerably less nausea than the control group in the first 6 hours (P = 0.019). At 0–72 hours after surgery, the incidences of nausea, retching, and vomiting in the 0.075 mg palonosetron group were considerably lower than in the 0.05 mg palonosetron or saline groups (P 0.001). Conclusion:PONV was decreased more efficiently in the 0.075 mg palonosetron group than in the 0.05 mg palonosetron and control groups in neurosurgicalpatients.